- Becton Dickinson (BDX) is a leading global medical technology company specializing in medical devices and equipment, with a market capitalization of $74.2 billion as of April 2026.
- In the past year, BDX completed the $17.5 billion sale of its biosciences and diagnostics unit to Waters Corporation, while also reporting a revenue of $5.25 billion in Q1 2026 despite lowering its profit forecast due to macroeconomic pressures.
- Key customers include healthcare providers and hospitals, with notable partnerships focused on advancing vascular access and digital health solutions, contributing to a 13% increase in their Acute Patient Management segment.
- BDX's ideal buyers are healthcare administrators and procurement officers looking for innovative medical solutions that enhance patient care and operational efficiency, particularly as the company pivots towards new growth strategies post-spin-off.
Becton Dickinson's workforce is organized into six departments, with Operations leading at four employees, followed by Information Technology and Human Resources, each with two employees. This distribution indicates a strong focus on operational efficiency and support functions. The presence of smaller departments such as Marketing and Legal reflects a streamlined approach to specialized functions within the organization.
The company operates primarily from a single location in San Diego, CA, which houses two employees. The remaining nine employees are distributed across other locations, highlighting a predominantly centralized workforce. This concentration suggests a strategic emphasis on operational efficiency and collaboration within a limited geographic footprint.
